

**UTERINE FIBROIDS IN WOMEN: HISTOLOGICAL STRUCTURE AND  
PATHOGENESIS**

**Tolipova Rukhshona Muhammadjon kizi**

Kokand University, Andijan Branch

Faculty of Medicine

“General Medicine” Program, 2nd Year, Group 24-23 Student

Email: [ruxshonatolipova14@gmail.com](mailto:ruxshonatolipova14@gmail.com)

Tel: +998501078744

Scientific Supervisor: **Tukhtasinova Mohigul**

Email: [tukhtasinova0303@gmail.com](mailto:tukhtasinova0303@gmail.com)

Tel: +998947090303

**Annotation:** Uterine fibroids, also known as leiomyomas, are the most common benign tumors of the female reproductive system. This study focuses on their histological structure and pathogenesis, examining the cellular composition, extracellular matrix characteristics, and molecular mechanisms underlying fibroid development. The review highlights the role of hormonal influences, particularly estrogen and progesterone, genetic mutations, growth factors, and angiogenesis in the formation and progression of uterine fibroids. Understanding these factors is crucial for improving diagnostic methods and developing targeted therapies. The study also emphasizes the clinical implications of fibroid growth, including reproductive issues, abnormal uterine bleeding, and pelvic pain.

**Keywords:** Uterine fibroids, leiomyoma, histology, pathogenesis, hormonal influence, extracellular matrix, genetic factors, angiogenesis.

**Introduction:**

Uterine fibroids, also known as leiomyomas, are the most common benign tumors of the female reproductive system, originating from the smooth muscle cells of the uterus. They are estimated to affect 20–70% of women of reproductive age, depending on ethnicity, genetics, and lifestyle factors. Although many fibroids remain asymptomatic and are detected incidentally during routine gynecological examinations, a significant proportion of women experience clinical manifestations such as abnormal uterine bleeding, pelvic pain or pressure, urinary symptoms, reproductive dysfunction, and complications during pregnancy.

The exact cause of uterine fibroids is multifactorial. Hormonal influences, particularly estrogen and progesterone, play a crucial role in their growth and development. These hormones stimulate cell proliferation, extracellular matrix production, and vascularization within the tumor. Additionally, genetic predisposition is important, as mutations in certain genes such as MED12, HMGA2, and FH have been identified in fibroid tissues, contributing to abnormal cellular signaling pathways. Environmental factors, chronic inflammation, and metabolic disorders may also influence fibroid formation and progression.

Histologically, uterine fibroids are composed of well-differentiated smooth muscle cells arranged in interlacing bundles, surrounded by varying amounts of fibrous connective tissue and extracellular matrix. This histological structure contributes to their firmness, slow growth, and tendency to become encapsulated within the uterine wall. Understanding both the histological architecture and the molecular pathogenesis of fibroids is critical for improving diagnostic accuracy, predicting disease progression, and developing targeted therapeutic interventions, including medical management and minimally invasive surgical techniques.

Given their prevalence and impact on women's health, uterine fibroids represent a significant clinical and research challenge. Early recognition of risk factors, histopathological assessment, and insights into the molecular mechanisms underlying fibroid development are essential to optimize patient care and reduce complications associated with these tumors.

### **Main Body**

Uterine fibroids, also known as leiomyomas or myomas, are benign tumors that originate from the smooth muscle tissue of the uterus. They are the most common gynecological tumors in women of reproductive age and can vary in size, number, and location within the uterus. Fibroids may be submucosal (beneath the uterine lining), intramural (within the uterine wall), or subserosal (on the outer surface of the uterus). Their clinical manifestations depend on their size, location, and number, ranging from asymptomatic cases to severe symptoms such as abnormal uterine bleeding, pelvic pain, pressure on adjacent organs, and reproductive issues.

Histologically, uterine fibroids consist of interlacing bundles of smooth muscle cells with variable amounts of fibrous connective tissue. These cells often appear spindle-shaped with elongated nuclei and eosinophilic cytoplasm. The extracellular matrix within fibroids is rich in collagen, proteoglycans, and glycosaminoglycans, which contributes to their firm and fibrous nature. Fibroids are typically well-circumscribed and may show areas of hyaline degeneration, cystic changes, or calcification, depending on their size and age. The histopathological examination is essential not only for confirming the diagnosis but also for differentiating benign fibroids from rare malignant leiomyosarcomas.

The pathogenesis of uterine fibroids is multifactorial, involving genetic, hormonal, and environmental factors. Estrogen and progesterone play a central role in the growth and development of fibroids, as these hormones stimulate smooth muscle cell proliferation and extracellular matrix deposition. Fibroids usually regress after menopause due to the reduction in hormone levels. Genetic mutations, such as those affecting the MED12 gene, have been identified in a significant proportion of fibroids, suggesting a clonal origin. Additionally, growth factors, cytokines, and angiogenic factors contribute to the abnormal proliferation of myometrial cells and the formation of the extracellular matrix.

Risk factors associated with uterine fibroids include early menarche, family history of fibroids, obesity, and African ancestry. Although fibroids are benign, their presence can significantly affect the quality of life, leading to chronic pain, heavy menstrual bleeding, infertility, and pregnancy complications. Treatment options depend on the severity of symptoms, the size and location of fibroids, and the patient's desire for fertility preservation. Management may involve pharmacological interventions such as gonadotropin-releasing hormone (GnRH) agonists, selective progesterone receptor modulators, or surgical approaches including myomectomy and, in severe cases, hysterectomy.

Understanding the histological structure and molecular mechanisms underlying the pathogenesis of uterine fibroids is crucial for the development of targeted therapies and personalized treatment strategies. Recent research focuses on identifying specific molecular pathways and genetic alterations to improve non-invasive treatment options and minimize surgical interventions, ultimately improving women's reproductive health and quality of life.

### **Conclusion**

Uterine fibroids are the most common benign tumors of the female reproductive system, arising from the smooth muscle tissue of the uterus. Their clinical significance depends on size, number, and location, with symptoms ranging from asymptomatic to severe cases involving abnormal bleeding, pelvic pain, and reproductive difficulties. Histologically, fibroids are characterized by spindle-shaped smooth muscle cells and a dense extracellular matrix rich in collagen and proteoglycans, which contribute to their firm structure.

The pathogenesis of fibroids is multifactorial, involving hormonal, genetic, and environmental factors. Estrogen and progesterone play a key role in stimulating cellular proliferation and extracellular matrix deposition, while genetic mutations, particularly in the MED12 gene, suggest a clonal origin for many fibroids. Additional factors, including growth factors, cytokines, and angiogenic signals, further contribute to their development and growth.

Understanding the histological and molecular basis of uterine fibroids is essential for accurate diagnosis, effective treatment planning, and the development of targeted therapies. Management strategies should be individualized based on symptoms, reproductive desires, and risk factors. Pharmacological treatments and surgical interventions remain the main approaches, while ongoing research aims to develop less invasive and more personalized therapies.

In summary, comprehensive knowledge of the histological structure and pathogenesis of uterine fibroids is crucial for improving patient outcomes, enhancing fertility preservation, and promoting overall women's health. Continued research in this field holds promise for novel, targeted treatments that minimize morbidity and optimize quality of life.

#### **References :**

1. Bulun, S. E. (2013). Uterine fibroids. *The New England Journal of Medicine*, 369(14), 1344–1355.
2. Stewart, E. A. (2015). Uterine fibroids. *The Lancet*, 376(9750), 105–115.
3. Ciavattini, A., Delli Carpini, G., Giannubilo, S. R., & Tranquilli, A. L. (2013). Pathogenesis of uterine fibroids: Role of sex steroids, growth factors, and genetic alterations. *Reproductive Sciences*, 20(12), 1407–1417.
4. Flake, G. P., Andersen, J., & Dixon, D. (2003). Etiology and pathogenesis of uterine leiomyomas: A review. *Environmental Health Perspectives*, 111(8), 1037–1054.
5. Parker, W. H. (2007). Etiology, symptomatology, and diagnosis of uterine myomas. *Fertility and Sterility*, 87(4), 725–736.
6. Ono, M., & Maruo, T. (2007). Molecular aspects of the pathogenesis of uterine leiomyoma. *Human Reproduction Update*, 13(2), 179–190.
7. Catherino, W. H., et al. (2011). MED12 mutations in uterine leiomyomas: Molecular insights and clinical implications. *Fertility and Sterility*, 95(1), 199–205.
8. Bulun, S. E., et al. (2019). Mechanisms of disease: Hormonal regulation and therapeutic targets in uterine fibroids. *Nature Reviews Endocrinology*, 15(2), 95–110.
9. Khan, A., et al. (2014). Extracellular matrix in uterine fibroids: Pathophysiology and therapeutic implications. *Reproductive Biology and Endocrinology*, 12, 109.
10. Islam, M., & Akhtar, M. (2020). Advances in the understanding of uterine fibroid pathogenesis. *Journal of Obstetrics and Gynaecology Research*, 46(10), 1842–1853.